Bristol-Myers Squibb Assets & Liabilities Overview 2006-2018 | BMY

Current and historical assets & liabilities overview for Bristol-Myers Squibb (BMY) from 2006 to 2018.
Bristol-Myers Squibb Annual Assets & Liabilities Overview
(Millions of US $)
Bristol-Myers Squibb Quarterly Assets & Liabilities Overview
(Millions of US $)
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $80.981B $22.561B
Bristol-Myers Squibb is a differentiated company, led by their unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. They work every day to deliver innovative medicines for patients with serious and life-threatening diseases. Their employees around the world work together for patients - it drives everything they do. They are focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis. Through their R&D organization, they have built a sustainable pipeline of potential therapies, and actively partner to access external innovation to broaden and accelerate their work.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $371.421B 16.92
Pfizer (PFE) United States $251.806B 14.10
Merck (MRK) United States $220.845B 18.87
Novartis AG (NVS) Switzerland $214.807B 18.27
Eli Lilly (LLY) United States $131.074B 22.77
Novo Nordisk (NVO) Denmark $127.625B 20.64
AbbVie (ABBV) United States $119.216B 10.22
Sanofi (SNY) France $113.215B 13.98
AstraZeneca (AZN) United Kingdom $108.585B 12.39
GlaxoSmithKline (GSK) United Kingdom $100.340B 13.18